Amneal Pharmaceuticals, INC. (AMRX) — SEC Filings

Latest SEC filings for Amneal Pharmaceuticals, INC.. Recent DEFA14A filing on Mar 25, 2026. AI-decoded analysis of earnings, risk factors, and insider trad

View Amneal Pharmaceuticals, INC. on SEC EDGAR

Overview

Amneal Pharmaceuticals, INC. (AMRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Mar 25, 2026: Amneal Pharmaceuticals, Inc. filed a DEFA14A on March 25, 2026, which are additional definitive proxy soliciting materials. This filing, identified by accession number 0001308179-26-000144, indicates the company is actively seeking shareholder votes, likely for an upcoming annual meeting or a specif

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 32 neutral, 2 mixed. The dominant filing sentiment for Amneal Pharmaceuticals, INC. is neutral.

Filing Type Overview

Amneal Pharmaceuticals, INC. (AMRX) has filed 1 DEFA14A, 6 10-Q, 15 8-K, 1 8-K/A, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 3 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (34)

Amneal Pharma Files Additional Proxy Materials on March 25, 2026 — DEFA14A · Mar 25, 2026
Amneal Pharmaceuticals, Inc. filed a DEFA14A on March 25, 2026, which are additional definitive proxy soliciting materials. This filing, identified by accession
Amneal Revenue Jumps 11.7% in Q3, Refinancing Costs Hit Profit — 10-Q · Nov 6, 2025 Risk: medium
Amneal Pharmaceuticals, Inc. (AMRX) reported a significant increase in net revenue for the three months ended September 30, 2025, reaching $784.5 million, up fr
Amneal Pharmaceuticals Files 8-K on Financials — 8-K · Oct 30, 2025 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on October 30, 2025, reporting on its results of operations and financial condition. The filing also includes Regulati
Amneal Pharmaceuticals Files Q2 2025 10-Q — 10-Q · Aug 7, 2025 Risk: low
Amneal Pharmaceuticals, Inc. filed its quarterly report for the period ended June 30, 2025. The company is incorporated in Delaware and its Class A Common Stock
Amneal Pharmaceuticals Files 8-K/A Amendment — 8-K/A · Aug 5, 2025 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K/A on August 5, 2025, to amend a previous filing. The amendment pertains to the submission of matters to a vote of secu
Amneal Pharmaceuticals Enters Material Agreement, Incurs Financial Obligation — 8-K · Aug 1, 2025 Risk: medium
On August 1, 2025, Amneal Pharmaceuticals, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obli
Amneal Pharmaceuticals Files 8-K Report — 8-K · Jul 24, 2025 Risk: low
On July 24, 2025, Amneal Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
Amneal Pharmaceuticals Files 8-K on Operations and Personnel — 8-K · Jul 21, 2025 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on July 21, 2025, reporting on events as of July 16, 2025. The filing covers results of operations, financial conditio
Amneal Pharmaceuticals Files 8-K Report — 8-K · Jul 21, 2025 Risk: low
On July 21, 2025, Amneal Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with n
Amneal Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · May 8, 2025 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on May 8, 2025, to report on matters submitted to a vote of its security holders. The filing does not detail the speci
Amneal Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 7, 2025 Risk: low
Amneal Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The filing details financial performance and operational updates f
Amneal Pharmaceuticals Files 8-K on Financials — 8-K · May 2, 2025 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on May 2, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financia
Amneal Pharma Proxy: Exec Pay & Board Nominee Details — DEF 14A · Mar 25, 2025 Risk: medium
Amneal Pharmaceuticals, Inc. filed its definitive proxy statement on March 25, 2025, for its annual meeting on May 6, 2025. The filing details executive compens
Amneal Pharmaceuticals Reports Director/Officer Changes — 8-K · Mar 6, 2025 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on March 6, 2025, reporting on the departure of directors, election of directors, appointment of officers, and compens
Amneal Pharmaceuticals Files 2024 10-K — 10-K · Feb 28, 2025 Risk: medium
Amneal Pharmaceuticals, Inc. filed its 2024 10-K report on February 28, 2025, detailing its financial performance for the fiscal year ending December 31, 2024.
Amneal Pharmaceuticals Files 8-K on Financials — 8-K · Jan 15, 2025 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on January 15, 2025, to report results of operations and financial condition, as well as a Regulation FD disclosure. T
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
Amneal Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Amneal Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the year,
Amneal Pharmaceuticals Files 8-K for Q3 2024 Results — 8-K · Nov 8, 2024 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on November 8, 2024, reporting on its results of operations and financial condition for the period ending September 30
Patel Amends Amneal Stake Filing — SC 13D/A · Oct 31, 2024 Risk: medium
Chirag Patel, through an amendment filed on October 31, 2024, has updated his Schedule 13D filing regarding Amneal Pharmaceuticals, Inc. The filing indicates a
Amneal Pharmaceuticals Files 8-K — 8-K · Oct 1, 2024 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on October 1, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filin
Amneal Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
Amneal Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second
Patel Amends Amneal Pharma Stake Filing — SC 13D/A · May 13, 2024 Risk: medium
On May 9, 2024, Tushar Bhikhubhai Patel filed an amendment (Amendment No. 4) to Schedule 13D for Amneal Pharmaceuticals, Inc. The filing indicates a change in b
Amneal Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: medium
Amneal Pharmaceuticals, Inc. (AMRX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Amneal Pharmaceuticals, Inc. filed its quarterly report (10-Q)
Amneal Pharmaceuticals Files 8-K on Shareholder Vote — 8-K · May 7, 2024 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on May 7, 2024, reporting on matters submitted to a vote of security holders on May 2, 2024. The filing does not conta
Amneal Pharmaceuticals Files 8-K on Financials — 8-K · May 3, 2024 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on May 3, 2024, reporting on its results of operations and financial condition. The filing also includes information r
SC 13G/A Filing — SC 13G/A · Apr 24, 2024
Amneal Pharmaceuticals, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Mar 22, 2024 Risk:
Amneal Pharmaceuticals, Inc. (AMRX) filed a Proxy Statement (DEF 14A) with the SEC on March 22, 2024. Filing Type: DEF 14A (Definitive Proxy Statement). Reporti
Amneal Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 14, 2024 Risk: medium
Amneal Pharmaceuticals, Inc. (AMRX) filed a Annual Report (10-K) with the SEC on March 14, 2024. Amneal Pharmaceuticals, Inc. filed its annual report on Form 10
Amneal Pharmaceuticals Files 8-K on Financials — 8-K · Mar 1, 2024 Risk: low
Amneal Pharmaceuticals, Inc. filed an 8-K on March 1, 2024, to report on its results of operations and financial condition. The filing also includes Regulation
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Amneal Pharma Files 8-K on Operations & Financial Condition — 8-K · Jan 10, 2024
Amneal Pharmaceuticals, Inc. filed an 8-K on January 10, 2024, to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'.
Mahesh Akram Discloses 30.38M Share Stake in Amneal Pharma — SC 13G · Jan 5, 2024
Mahesh Akram, an individual, reported beneficial ownership of 30,384,769 shares of Amneal Pharmaceuticals, Inc. Class A Common Stock as of January 1, 2024. This
Gautam Patel Joins Group in Amneal Pharma, Signaling Potential Activism — SC 13D/A · Jan 3, 2024
Gautam Patel, a significant shareholder in Amneal Pharmaceuticals, Inc., filed an Amendment No. 5 to his Schedule 13D on January 1, 2024. This filing indicates

Frequently Asked Questions

What are the latest SEC filings for Amneal Pharmaceuticals, INC. (AMRX)?

Amneal Pharmaceuticals, INC. has 34 recent SEC filings from Jan 2024 to Mar 2026, including 15 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AMRX filings?

Across 34 filings, the sentiment breakdown is: 32 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Amneal Pharmaceuticals, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Amneal Pharmaceuticals, INC. (AMRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.